Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen Reports Preliminary Q1 Revenue Growth of 9 Percent

NEW YORK – Qiagen said on Thursday that its first quarter revenues and earnings per share are expected to be significantly higher than previously issued guidance, primarily due to sales of products used in COVID-19 testing.

For the three months ended March 31, 2020, Qiagen reported preliminary revenue growth of 9 percent at constant exchange rates, compared to a prior outlook, issued on Feb. 4, of approximately 2 percent to 3 percent growth.

Sales reflected "very significant" demand for products used in COVID-19 testing against weaker customer demand in other product areas.

Qiagen reported preliminary adjusted earnings per share of approximately $.34 to $.35 compared to previous guidance of $.28 to $.29. On average, analysts are expecting EPS of $.28 for the quarter.

Qiagen is in the midst of being acquired by Thermo Fisher Scientific for $11.5 billion, a deal that is expected to close in the first half of 2021.

In mid-afternoon Thursday trading on the New York Stock Exchange, Qiagen's share were down a fraction of a percent at $39.35.

The Scan

Foxtail Millet Pangenome, Graph-Based Reference Genome

Researchers in Nature Genetics described their generation of a foxtail millet pangenome, which they say can help in crop trait improvement.

Protein Length Distribution Consistent Across Species

An analysis in Genome Biology compares the lengths of proteins across more than 2,300 species, finding similar length distributions.

Novel Genetic Loci Linked to Insulin Resistance in New Study

A team reports in Nature Genetics that it used glucose challenge test data to home in on candidate genes involved in GLUT4 expression or trafficking.

RNA Editing in Octopuses Seems to Help Acclimation to Shifts in Water Temperature

A paper in Cell reports that octopuses use RNA editing to help them adjust to different water temperatures.